$ABT (Abbott Laboratories)

$ABT {{ '2015-07-22T12:56:28+0000' | timeago}} • Announcement

$ABT 2Q15 PR: For FY15, EPS from continuing operations, excluding specified items, is expected to be $2.10-2.20. Net specified items related to continuing operations for FY15 are forecasted to be approx. $0.60 per share. Including net specified items, full-year 2015 GAAP EPS from continuing operations is expected to be $1.50-1.60.

$ABT {{ '2017-10-20T18:04:31+0000' | timeago}} • Webcast

$ABT stated that regarding Alere, the company expects it to contribute around $475MM to its reported sales in FY17 and forecasts a neutral impact on adjusted EPS for the year. For FY17, $ABT continues to forecast comparable operational sales growth in the mid-single digits.

$ABT {{ '2017-10-20T17:56:19+0000' | timeago}} • Webcast

$ABT continues to anticipate CE Mark for its Alinity molecular diagnostic systems in the coming months and expect to begin the launch of the Alinity instruments in the US in 2018. In nutrition business outside China, the company expects to see soft market conditions across few international markets.

$ABT {{ '2017-10-18T18:04:16+0000' | timeago}} • Announcement

$ABT narrowed its FY17 EPS outlook range, which continues to reflect double-digit growth. The company now expects GAAP EPS to be $0.97-0.99 for FY17, while adjusted diluted EPS is now expected in the range of $2.48-2.50, which represents an increase at the mid-point of the guidance range. For 4Q17, $ABT expects EPS to be $0.28-$0.30.

$ABT {{ '2017-10-18T17:33:26+0000' | timeago}} • Announcement

$ABT swung to profit in 3Q17 on higher device sales and benefits from St. Jude Medical acquisition. Strength in medical devices business helped the company post a profit of $603MM or $0.32 per share from a loss of $329MM or $0.24 per share a year ago. Net sales jumped 28.8% to $6.8Bil, with adjusted EPS climbing 12% to $0.66 per share.

$ABT {{ '2017-10-18T13:13:48+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q3 2017 Highlights

$ABT {{ '2017-10-02T12:48:41+0000' | timeago}} • Announcement

$ABT extended tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share. The Offer is being extended to allow additional time for the consummation of the Merger. The offer will now expire on Oct. 3, 2017.

$ABT {{ '2017-09-29T14:25:12+0000' | timeago}} • Announcement

$ABT said it plans to close the acquisition of $ALR on October 3, 2017.  With the addition of $ALR, $ABT will have approx. $7Bil in diagnostics sales worldwide, including approx. $2.5Bil on point of care testing.

$ABT {{ '2017-09-22T12:26:48+0000' | timeago}} • Announcement

$ABT got the FDA nod for magnetic resonance (MR)-conditional labeling for its implantable cardioverter defibrillators (ICD) and associated high voltage leads. The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan. Patients implanted with Ellipse device and Durata or Optisure leads can also undergo MRI scans.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$ABT {{ '2017-09-01T12:22:31+0000' | timeago}} • Announcement

$ABT said it is extending its tender offer to buy for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere at $402 per share. The offer will now expire on Sept. 15, 2017.

$ABT {{ '2017-08-31T13:43:11+0000' | timeago}} • Announcement

$ABT said the Ministry of Health Labour and Welfare in Japan has granted national reimbursement for the FreeStyle Libre glucose monitoring system effective Sept. 1, 2017. The revolutionary system will be widely available to the more than 1MM Japanese people ages six and above with diabetes, both Type 1 and Type 2, on insulin therapy.

$ABT {{ '2017-08-30T16:14:21+0000' | timeago}} • Announcement

$ABT initiated U.S. pivotal clinical study evaluating safety and effectiveness of modified version of its Amplatzer device designed to correct common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year. Patent ductus arteriosus is a common heart defect, accounting for 5-10% of all congenital heart disease.

$ABT {{ '2017-08-30T16:03:53+0000' | timeago}} • Announcement

$ABT announced regulatory approval in Russia and the Netherlands for a new indication for its oral dydrogesterone medicine. Oral dydrogesterone, which has been used to treat progesterone insufficiency conditions, is now approved in these countries as treatment option to prepare uterus in women who undergo in vitro fertilization (IVF) treatment.

$ABT {{ '2017-08-29T16:14:25+0000' | timeago}} • Announcement

$ABT issued new updates for implanted cardiac devices. $ABT notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The planned updates are designed to provide new patient management tools and further protection against unauthorized access.

$ABT {{ '2017-08-28T13:50:49+0000' | timeago}} • Announcement

$ABT designed the HeartMate 3 system to take LVAD therapy further. In developing the HeartMate 3 system, the company reduced the system's size while reimagining how blood passes through an LVAD. This system deploys Full MagLev technology to reduce trauma to the blood passing through the pump while optimizing blood flow.

$ABT {{ '2017-08-28T13:35:49+0000' | timeago}} • Announcement

$ABT received U.S. FDA approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need of short-term hemodynamic support and provides patients living with their device new benefits that embody the evolution of LVAD therapy.

$ABT {{ '2017-08-15T12:37:58+0000' | timeago}} • Announcement

North West London Pathology (NWLP) and $ABT signed a $252MM managed equipment services contract for the supply of all analytical equipment and consumables. This includes $ABT's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.

$ABT {{ '2017-08-14T12:19:03+0000' | timeago}} • Announcement

$ABT said it is extending its tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock at a price of $402 per share. The Offer was previously scheduled to expire on Aug. 11, 2017 and will now expire on Aug. 31, 2017.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
TSRO (Tesaro, Inc.)
Tuesday, August 8 2017 - 8:15pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
CYTK (Cytokinetics, Incorporated)
Wednesday, August 2 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, August 2 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Thursday, July 27 2017 - 8:30pm
ABAX (Abaxis, Inc.)
Thursday, July 27 2017 - 8:15pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
INVA (Innoviva, Inc.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
KO (The Coca-Cola Company)
Wednesday, July 26 2017 - 1:00pm

AlphaGraphics you may like